Moleculin Biotech, Inc.
Symbol: MBRX (NASDAQ)
0.40
▼ (-2.91%) -0.012
Company Description:
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Key Stats
- Today's Open: $0.41
- Today's High: $0.415
- Today's Low: $0.396
- Today's Volume: 2.41M
- Yesterday Close: $0.412
- Yesterday High: $0.42
- Yesterday Low: $0.387
- Yesterday Volume: 3.62M
- Last Min Volume: 1
- Last Min High: $0.4
- Last Min Low: $0.4
- Last Min VWAP: $0.4
Company Profile
- Name: Moleculin Biotech, Inc.
- Website: https://www.moleculin.com
- Listed Date: 2016-06-02
- Location: HOUSTON, TX
- Market Status: Active
- CIK Number: 0001659617
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $12.20M
- Round Lot: 100
- Outstanding Shares: 30.29M
- Asset Type: CS
RECENT FILINGS FOR MBRX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-19 | S-3 | View |
| 2025-09-15 | DEF 14A | View |
| 2025-09-10 | S-8 | View |
| 2025-09-09 | 8-K | View |
| 2025-09-08 | 8-K | View |
| 2025-09-08 | 8-K | View |
| 2025-09-05 | PRE 14A | View |
| 2025-08-29 | 8-K | View |
| 2025-08-27 | 8-K | View |
| 2025-08-18 | 8-K | View |
| 2025-08-18 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-08-01 | 8-K | View |
| 2025-07-30 | 8-K | View |
| 2025-07-17 | 8-K | View |
| 2025-07-11 | 8-K | View |
| 2025-07-11 | 424B5 | View |
Latest News on MBRX